1. Pardridge WM. Introduction to the blood-brain barrier. Cambridge University Press, 1998.
2. Begley DJ, Brightman MW. Structural and functional aspects of
the blood-brain barrier. Prog Drug Res 61:39 –78, 2003. 25.
3. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev
84:869 –901, 2004. 26.
4. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al.
Size-selective loosening of the blood-brain barrier in claudin-5- deficient mice. J Cell Biol 161:653– 660, 2003.
5. Segal MB. The choroid plexuses and the barriers between the 27.
blood and the cerebrospinal fluid. Cell Mol Neurobiol 20:183–
196, 2000.
6. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the
central nervous system: brain barriers and brain parenchyma con- 28.
siderations. Pharmacol Rev 53:569 –596, 2001.
7. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at
the blood-brain barrier and blood-cerebrospinal fluid barrier (Part
1). Drug Discov Today 6:150 –156, 2001.
8. Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in 29.
the CNS. Adv Drug Deliv Rev 55:83–105, 2003.
9. Begley DJ. ABC transporters and the blood-brain barrier. Curr
Pharm Des 10:1295–1312, 2004
10. Lin JH. How significant is the role of P-glycoprotein in drug 30.
absorption and brain uptake? Drugs Today (Barc) 40:5–22, 2004
11. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain
barrier. Adv Drug Deliv Rev 36:179 –194, 1999
12. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug 31.
transporter studies on drug discovery and development. Pharmacol Rev 55:425– 461, 2003.
13. Sakata A, Tamai I, Kawazu K, Deguchi Y, Ohnishi T, Saheki A, 32.
et al. In vivo evidence for ATP-dependent and P-glycoproteinmediated transport of cyclosporin A at the blood-brain barrier.
Biochem Pharmacol 48:1989 –1992, 1994.
14. Ohnishi T, Tamai I, Sakanaka K, Sakata A, Yamashima T, Ya- 33.
mashita J, et al. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the
blood-brain barrier. Biochem Pharmacol 49:1541–1544, 1995.
15. Hagenbuch B, Meier PJ. The superfamily of organic anion trans- 34.
porting polypeptides. Biochim Biophys Acta 1609:1–18, 2003.
16. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides
of the OATP/ SLC21 family: phylogenetic classification as 35.
OATP/ SLCO superfamily, new nomenclature and molecular/
functional properties. Pflugers Arch 447:653– 665, 2004.
17. Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M,
et al. Molecular characterization and tissue distribution of a new
organic anion transporter subtype (oatp3) that transports thyroid 36.
hormones and taurocholate and comparison with oatp2. J Biol
Chem 273:22395–22401, 1998.
18. Noe B, Hagenbuch B, Stieger B, Meier PJ. Isolation of a multi- 37.
specific organic anion and cardiac glycoside transporter from rat
brain. Proc Natl Acad Sci USA 94:10346 –10350, 1997.
19. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of
the organic anion transporting polypeptide 2 (Oatp2) in capillary 38.
endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255–1264, 1999.
20. Reichel C, Gao B, Van Montfoort J, Cattori V, Rahner C, Hagenbuch B, et al. Localization and function of the organic anion- 39.
transporting polypeptide Oatp2 in rat liver. Gastroenterology
117:688 – 695, 1999.
21. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, 40.
Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol
Exp Ther 294:73–79, 2000. 41.
22. van Montfoort JE, Hagenbuch B, Fattinger KE, Muller M,
Groothuis GM, Meijer DK, et al. Polyspecific organic anion
